EUVIMEDEUVIMED entdecken
Open Access

Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients

Alastair L Smith iD, Nicholas Denny, Catherine Chahrour iD, Kim Sharp, Marta Arachi, Ana M Dopico-Fernandez iD, Natalina Elliott iD, Joe R Harman, Thomas Jackson, Huimin Geng, Owen Smith, Jonathan Bond iD und 6 weitere

Blood · 2025

DOI: 10.1182/blood.2024028019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, 2025. Verfasst von Alastair L Smith und 17 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxfo…. Hauptthemen laut MEDLINE: Enhancer Elements, Genetic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Gene Expression Regulation, Leukemic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genetic alterations alone cannot account for the diverse phenotypes of cancer cells. Even cancers with the same driver mutation show significant transcriptional heterogeneity and varied responses to therapy. However, the mechanisms underpinning this heterogeneity remain underexplored. Here, we find that novel enhancer usage is a common feature in acute lymphoblastic leukemia (ALL). In particular, KMT2A::AFF1 ALL, an aggressive leukemia with a poor prognosis and a low mutational burden, exhibits substantial transcriptional heterogeneity between individuals. Using single-cell multiome analysis and extensive chromatin profiling, we reveal that much transcriptional heterogeneity in KMT2A::AFF1 ALL is driven by novel enhancer usage. By generating high-resolution Micro Capture-C data in primary patient samples, we identify patient-specific enhancer activity at key oncogenes such as MEIS1 and RUNX2, driving high levels of expression of both oncogenes in a patient-specific manner. Overall, our data show that enhancer heterogeneity is highly prevalent in KMT2A::AFF1 ALL and may be a mechanism that drives transcriptional heterogeneity in cancer more generally.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enhancer Elements, GeneticPrecursor Cell Lymphoblastic Leukemia-LymphomaGene Expression Regulation, LeukemicGenetic HeterogeneityHistone-Lysine N-MethyltransferaseMyeloid-Lymphoid Leukemia ProteinOncogene Proteins, FusionMyeloid Ecotropic Viral Integration Site 1 ProteinCore Binding Factor Alpha 1 SubunitDNA-Binding ProteinsTranscriptional Elongation FactorsWhole Genome SequencingGene Expression ProfilingHumansMaleFemaleInfant, NewbornInfantChild, PreschoolChildAdolescent

Substanzen

KMT2A protein, humanAFF1 protein, humanHistone-Lysine N-MethyltransferaseMyeloid-Lymphoid Leukemia ProteinOncogene Proteins, FusionMEIS1 protein, humanMyeloid Ecotropic Viral Integration Site 1 ProteinRUNX2 protein, humanCore Binding Factor Alpha 1 SubunitDNA-Binding Proteins

Autor:innen und Institutionen

  • Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
  • Dark Blue Therapeutics Ltd, Oxford, United Kingdom.
  • Department of Laboratory Medicine, University of California, San Francisco, CA.
  • Trinity College, University of Dublin, Dublin, Ireland.
  • Systems Biology Ireland, School of Medicine, University College Dublin, Dublin, Ireland.

ORCID-Profile: Alastair L Smith, Catherine Chahrour, Ana M Dopico-Fernandez, Natalina Elliott, Jonathan Bond, Irene Roberts, Ronald W Stam, Nicholas T Crump, James O J Davies, Anindita Roy, Thomas A Milne

Förderung

  • Wellcome Trust

Zitieren

APA

Smith, A. L., Denny, N., Chahrour, C., Sharp, K., Arachi, M., Dopico-Fernandez, A. M., Elliott, N., Harman, J. R., Jackson, T., Geng, H., Smith, O., Bond, J., Roberts, I., Stam, R. W., Crump, N. T., Davies, J. O. J., Roy, A., & Milne, T. A. (2025). Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients. Blood. https://doi.org/10.1182/blood.2024028019

Vancouver

Smith AL, Denny N, Chahrour C, Sharp K, Arachi M, Dopico-Fernandez AM, et al. Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients. Blood. 2025. doi:10.1182/blood.2024028019

BibTeX
@article{Smith2025,
  author = {Smith, Alastair L and Denny, Nicholas and Chahrour, Catherine and Sharp, Kim and Arachi, Marta and Dopico-Fernandez, Ana M and Elliott, Natalina and Harman, Joe R and Jackson, Thomas and Geng, Huimin and Smith, Owen and Bond, Jonathan and Roberts, Irene and Stam, Ronald W and Crump, Nicholas T and Davies, James O J and Roy, Anindita and Milne, Thomas A},
  title = {Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients},
  journal = {Blood},
  year = {2025},
  doi = {10.1182/blood.2024028019}
}
Kostenlos starten →